{"id":4013,"date":"2012-04-16T13:29:00","date_gmt":"2012-04-16T13:29:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=4013"},"modified":"2021-07-09T11:27:02","modified_gmt":"2021-07-09T11:27:02","slug":"selective-granulocyte-and-monocyte-apheresis-as-a-non-pharmacological-option-for-patients-with-inflammatory-bowel-disease","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/selective-granulocyte-and-monocyte-apheresis-as-a-non-pharmacological-option-for-patients-with-inflammatory-bowel-disease\/","title":{"rendered":"Selective granulocyte and monocyte apheresis as a non-pharmacological option for patients with inflammatory bowel disease."},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=C+Leitner+G&amp;cauthor_id=22969694\">Gerda C Leitner<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22969694\/#affiliation-1\">1<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Worel+N&amp;cauthor_id=22969694\">Nina Worel<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Vogelsang+H&amp;cauthor_id=22969694\">Harald Vogelsang<\/a>, Transfus Med Hemother. 2012 Aug;39(4):246-252.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Ulcerative colitis and Crohn&#8217;s disease are the two most prevalent inflammatory bowel diseases. In both cases, the medically refractory and steroid-dependent type presents a therapeutic challenge. To help resolve this problem, a mainly Japanese team developed a new therapeutic option. There are two systems, both of which are able to selectively remove the main mediators of the disease, namely the activated pro-inflammatory cytokine-producing granulocytes and monocytes\/macrophages, from the patient&#8217;s blood circulation (GMA = granulocyte monocyte apheresis). One of the two systems is the Adacolumn( (\u00ae) ) (Immunoresearch Laboratories, Takasaki, Japan) consisting of the ADA-monitor and a single-use column, which contains approximately 35,000 cellulose acetate beads. The exact mode of action is not yet sufficiently understood, but however, a modulation of the immune system takes place. As a result, less pro-inflammatory cytokines are released. Furthermore, the production of anti-inflammatory interleukin-1 receptor antagonist is increased, and the apoptosis of granulocytes boosted. The decreased LECAM-1-expression on leukocytes impedes the leukotaxis to the inflamed tissue, and CD10-negative immature granulocytes appear in the peripheral blood. Another effect to be mentioned is the removal of the peripheral dendritic cells and the leachate of regulatory T cells (T-regs). The second system is the Cellsorba( (\u00ae) ) FX Filter (Asahi Medical, Tokyo, Japan). The range of efficiency, the indication, and the procedure are very similar to the Adacolumn. Solely the additional removal of lymphocytes can possibly limit the implementation since lymphopenia can increase the risk of autoimmune disease. Both systems provide a low-risk therapy with few adverse reactions. ASFA recommendations for GMA in inflammatory bowel disease are 2B due to the fact that not enough randomized double-blind studies are available to proof the efficacy of this treatment.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22969694\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/22969694\/<\/a><\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3434328\/pdf\/tmh-0039-0246.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3434328\/pdf\/tmh-0039-0246.pdf<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Gerda C Leitner&nbsp;1,&nbsp;Nina Worel,&nbsp;Harald Vogelsang, Transfus Med Hemother. 2012 Aug;39(4):246-252. Ulcerative colitis and Crohn&#8217;s disease are the two most prevalent inflammatory bowel diseases. In both cases, the medically refractory and steroid-dependent type presents a therapeutic challenge. To help resolve this problem, a mainly Japanese team developed a new therapeutic option. There are two systems, both [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[234,229,235,231,233,147,232,228,227,230,226,156,55,135,90],"class_list":["post-4013","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-adacolumn","scientific_tags-apoptosis","scientific_tags-asfa","scientific_tags-cd10","scientific_tags-cellsorba","scientific_tags-clinical-remission","scientific_tags-dc","scientific_tags-il1r","scientific_tags-immunological-effects","scientific_tags-lecam-1l-selectin","scientific_tags-non-pharmacological","scientific_tags-safety","scientific_tags-steroid-dependent","scientific_tags-steroid-refractory","scientific_tags-tregs"],"acf":{"sc_authors":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Selective granulocyte and monocyte apheresis as a non-pharmacological option for patients with inflammatory bowel disease. - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-and-monocyte-apheresis-as-a-non-pharmacological-option-for-patients-with-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Selective granulocyte and monocyte apheresis as a non-pharmacological option for patients with inflammatory bowel disease. - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Gerda C Leitner&nbsp;1,&nbsp;Nina Worel,&nbsp;Harald Vogelsang, Transfus Med Hemother. 2012 Aug;39(4):246-252. Ulcerative colitis and Crohn&#8217;s disease are the two most prevalent inflammatory bowel diseases. In both cases, the medically refractory and steroid-dependent type presents a therapeutic challenge. To help resolve this problem, a mainly Japanese team developed a new therapeutic option. There are two systems, both [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-and-monocyte-apheresis-as-a-non-pharmacological-option-for-patients-with-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-09T11:27:02+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-and-monocyte-apheresis-as-a-non-pharmacological-option-for-patients-with-inflammatory-bowel-disease\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-and-monocyte-apheresis-as-a-non-pharmacological-option-for-patients-with-inflammatory-bowel-disease\/\",\"name\":\"Selective granulocyte and monocyte apheresis as a non-pharmacological option for patients with inflammatory bowel disease. - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2012-04-16T13:29:00+00:00\",\"dateModified\":\"2021-07-09T11:27:02+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-and-monocyte-apheresis-as-a-non-pharmacological-option-for-patients-with-inflammatory-bowel-disease\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Selective granulocyte and monocyte apheresis as a non-pharmacological option for patients with inflammatory bowel disease. - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-and-monocyte-apheresis-as-a-non-pharmacological-option-for-patients-with-inflammatory-bowel-disease\/","og_locale":"es_ES","og_type":"article","og_title":"Selective granulocyte and monocyte apheresis as a non-pharmacological option for patients with inflammatory bowel disease. - Adacyte","og_description":"Gerda C Leitner&nbsp;1,&nbsp;Nina Worel,&nbsp;Harald Vogelsang, Transfus Med Hemother. 2012 Aug;39(4):246-252. Ulcerative colitis and Crohn&#8217;s disease are the two most prevalent inflammatory bowel diseases. In both cases, the medically refractory and steroid-dependent type presents a therapeutic challenge. To help resolve this problem, a mainly Japanese team developed a new therapeutic option. There are two systems, both [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-and-monocyte-apheresis-as-a-non-pharmacological-option-for-patients-with-inflammatory-bowel-disease\/","og_site_name":"Adacyte","article_modified_time":"2021-07-09T11:27:02+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-and-monocyte-apheresis-as-a-non-pharmacological-option-for-patients-with-inflammatory-bowel-disease\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-and-monocyte-apheresis-as-a-non-pharmacological-option-for-patients-with-inflammatory-bowel-disease\/","name":"Selective granulocyte and monocyte apheresis as a non-pharmacological option for patients with inflammatory bowel disease. - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2012-04-16T13:29:00+00:00","dateModified":"2021-07-09T11:27:02+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-and-monocyte-apheresis-as-a-non-pharmacological-option-for-patients-with-inflammatory-bowel-disease\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/4013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=4013"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=4013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}